U.S. FDA Approves First Generic Version of Levaquin (MYL) (RDY) (TEVA) (AKRX)

The U.S. Food and Drug Administration today approved the first generic versions of Levaquin (levofloxacin), an antibiotic approved to treat certain infections in people ages 18 and older.

Generic tablet, oral solution, and injectable solution dosage forms of levofloxacin have been approved. The following 12 manufacturer's applications for generic levofloxacin have been approved:

• Akorn Inc. (Nasdaq: AKRX)
  
• Aurobindo Pharma Ltd.
  
• Dr. Reddy's Laboratories Ltd. (NYSE: RDY)
  
• Glenmark Generics Ltd.
  
• Hi-Tech Pharmacal Co. Inc.
  
• Lupin Ltd.
  
• Mylan Pharmaceuticals Inc. (NYSE: MYL)
  
• Sagent Strides LLC
  
• Sandoz Inc.
  
• Teva Pharmaceuticals USA (Nasdaq: TEVA)
  
• Torrent Pharmaceuticals Ltd.
  
• Wockhardt Ltd.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Sigma Lithium resumes full operations after signing TAC agreement
• Gray Media closes $750M note offering to refinance higher-rate debt